Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Japan Manufacturing Growth Accelerates in June as Orders Surge Despite Iran War Cost Pressures 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
